Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Current Deferred Revenue (2016 - 2021)

Arcadia Biosciences (RKDA) has disclosed Current Deferred Revenue for 8 consecutive years, with $63000.0 as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Current Deferred Revenue changed N/A year-over-year to $63000.0, compared with a TTM value of $63000.0 through Jun 2021, changed N/A, and an annual FY2020 reading of $8000.0, down 80.95% over the prior year.
  • Current Deferred Revenue was $63000.0 for Q2 2021 at Arcadia Biosciences, roughly flat from $63000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.0 million in Q4 2017 and bottomed at $8000.0 in Q4 2020.
  • Average Current Deferred Revenue over 5 years is $310875.0, with a median of $88000.0 recorded in 2018.
  • The sharpest move saw Current Deferred Revenue plummeted 96.81% in 2019, then surged 270.59% in 2021.
  • Year by year, Current Deferred Revenue stood at $1.0 million in 2017, then crashed by 90.4% to $96000.0 in 2018, then crashed by 56.25% to $42000.0 in 2019, then plummeted by 80.95% to $8000.0 in 2020, then surged by 687.5% to $63000.0 in 2021.
  • Business Quant data shows Current Deferred Revenue for RKDA at $63000.0 in Q2 2021, $63000.0 in Q1 2021, and $8000.0 in Q4 2020.